Gilead Sciences (GILD) Gets a Hold from RBC Capital
In a report released today, Brian Abrahams from RBC Capital maintained a Hold rating on Gilead Sciences (GILD – Research Report), with a price ...
Breaking Down Gilead Sciences: 22 Analysts Share Their Views
In the assessment of 12-month price targets, analysts unveil insights for Gilead Sciences, presenting an average target of ...
Cognizant, Gilead expand relationship
Cognizant (CTSH) has announced an expansion of its longstanding relationship with biopharmaceutical leader Gilead Sciences (GILD) that aims to ...
Business Wire7d
Gilead Sciences to Release Fourth Quarter & Full Year 2024 Financial Results on Tuesday, February 11, 2025
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its fourth quarter and full year 2024 financial results and 2025 ...